In Ewing sarcoma and some NSCLC cell lines, for example, inhibiting NAMPT does not create an imbalance in ROS, suggesting compensatory mechanisms maintain NAD+ levels.47–49 However, several studies have reported the efficacy of combining NAMPT inhibitors with ROS-inducing agents, resulting in excessive ROS production, which enhanced the efficacy of treatment against the growth of tumors.6–10. The gene discussed is NAMPT; the disease is non-small cell lung carcinoma.